Amniotic Membrane Compositions for Anti-Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating cellular and pathological processes lack effective compounds that can inhibit angiogenesis and reduce inflammation while protecting corneal and limbal epithelial cells from apoptosis, particularly in conditions like cancer and age-related macular degeneration.
Innovation Solution
Purified compositions derived from amniotic membrane preparations, including cross-linked high molecular weight hyaluronan, Tumor necrosis factor-stimulated gene 6, Pentraxin 3, Thrombospondin 1, and optionally Smad7, are used to inhibit angiogenesis, induce apoptosis in endothelial cells, and reduce inflammation by suppressing TGF-β signaling and cellular proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to modulate cellular processes, then general cellular activity is maintained, but angiogenesis inhibition and anti-inflammatory effects are insufficient
Solution Approach 1:
The patent extracts and purifies specific bioactive components (TSG-6, PTX-3, TSP-1, HA) from amniotic membrane preparations to create a composition with concentrated anti-angiogenic and anti-inflammatory activity. This extraction principle allows the isolated components to exert therapeutic effects without the complexity of whole tissue, directly addressing the insufficiency of conventional methods.
Solution Approach 2:
The invention combines multiple purified components (TSG-6, PTX-3, TSP-1, and HA) into a composite composition that synergistically inhibits angiogenesis and reduces inflammation. Each component contributes specific anti-angiogenic or anti-inflammatory properties, and their combination provides enhanced therapeutic efficacy compared to single agents.
2Object-affected harmful factors
If angiogenesis is inhibited to treat cancer and macular degeneration, then pathological vascular growth is reduced, but normal tissue repair processes may be affected
Solution Approach 1:
The patent applies the anti-angiogenic composition locally to pathological sites (such as tumor sites or sites of macular degeneration) rather than systemically. This localized application allows inhibition of pathological vascular growth at the target site while preserving normal angiogenesis and tissue repair processes in other areas of the body.
Solution Approach 2:
The purified components in the composition modulate angiogenesis by changing specific molecular parameters (such as TGF-β signaling pathways, VEGF expression levels) rather than causing broad suppression of all vascular processes. This parameter-specific modulation allows selective inhibition of pathological angiogenesis while maintaining normal physiological functions.
3Ease of manufacture
If amniotic membrane preparations are used directly, then source material is readily available, but purification and standardization are difficult
Solution Approach 1:
The patent segments the complex amniotic membrane preparation into individual purified components (TSG-6, PTX-3, TSP-1, HA). This segmentation allows each component to be isolated, characterized, and standardized separately, enabling precise control over composition and potency while maintaining the therapeutic benefits of the source material.
Solution Approach 2:
The purification process transforms the crude amniotic membrane extract into standardized compositions with defined concentrations of active components. This parameter change from crude to purified state enables consistent manufacturing quality, batch-to-batch reproducibility, and reliable dosing while preserving the therapeutic efficacy of the original preparation.
Data Source
AI summary
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.